Illumina secures FDA approval for comprehensive cancer test and two companion diagnostics
Illumina, Inc. (NASDAQ: ILMN), a global leader in the field of DNA sequencing and array-based technologies, has secured crucial approval from the Food and Drug Administration (FDA) for its TruSight Oncology (TSO) Comprehensive test. This approval marks a significant advancement in cancer diagnostics, as it also includes the FDA’s endorsement of two companion diagnostics (CDx) […]
